Premium
P2‐446: EMPLOYMENT DISCRIMINATION RISKS BASED ON PRECLINICAL ALZHEIMER'S DISEASE BIOMARKERS
Author(s) -
Arias Jalayne J.,
Karunungan Krystal,
Karlawish Jason
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.1138
Subject(s) - biomarker , disease , medicine , promotion (chess) , dementia , informed consent , psychology , pathology , alternative medicine , political science , biochemistry , chemistry , politics , law
Figure 2. Proportion of subjects in each category (normal vs abnormal) at each EBM stage. Proportion of negative scans in dark blue and positive scans in green. Each EBM stage on the x-axis corresponds to the occurrence of a new regional transition event. Stage 0 corresponds to no events having occurred and stage 20 is when all events have occurred. Events are ordered by the maximum likelihood event sequence for the whole population as shown in Figure 1.